.png)
NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and weight lowering than does escalating dulaglutide treatment. “Often, when we are with a patient who is not meeting treatment goals...
Dsn.sebani Ds.tanjangrono RT 04 RW 01 Mojokerto-Jawa Timur
+6281993868686
lita@gdrive.or.id
Copyright © 2023 saktinews. All Rights Reserved
